Management of Chronic Kidney Disease Stage 3b

Disease Classification and Risk Assessment

The patient's laboratory values indicate Stage 3b Chronic Kidney Disease (CKD) with a glomerular filtration rate (GFR) of 31 mL/min/1.73m², which is associated with moderate to severe reduction in kidney function and increased risk for progression to end-stage renal disease, according to the American Journal of Kidney Diseases 1
Patients with CKD and GFR <60 mL/min are at high risk for further ischemic events and adverse cardiovascular outcomes, as stated by the European Heart Journal 2

The European Heart Journal recommends that ACE inhibitors or ARBs should be initiated and titrated to maximally tolerated doses to reduce microalbuminuria, slow CKD progression, and reduce cardiovascular events 2, 3, 4
The European Heart Journal and Kidney International suggest monitoring serum creatinine after starting ACE inhibitors/ARBs, with an initial increase up to 30% being acceptable and usually returning to baseline 3, 4
Discontinue ACE inhibitors/ARBs if kidney function continues to worsen or if refractory hyperkalemia develops, as advised by Kidney International 4
Dose adjustment is required for many medications, such as Ramipril, with an initial dose of 1.25 mg daily if creatinine clearance (CrCl) <30 mL/min, not exceeding 5 mg/day, according to the European Heart Journal 3
Atenolol requires a half dose (50 mg/day) for CrCl between 15-35 mL/min, as recommended by the European Heart Journal 5

The Kidney International recommends a target systolic blood pressure of <120 mmHg using standardized office blood pressure measurement 4
Achieving a systolic blood pressure of 120-130 mmHg is often more realistic in patients with glomerular disease, as stated by Kidney International 4
Combination therapy may be necessary to achieve target blood pressure, according to Kidney International 4

Consider statin therapy for cardiovascular risk reduction in CKD patients, as recommended by the European Heart Journal 2
Restrict dietary sodium to <2.0 g/day (<90 mmol/day), as advised by Kidney International 4
For edema management, use loop diuretics as first-line therapy, preferably with twice daily dosing, according to Kidney International 4, 6
Consider switching to longer-acting loop diuretics (bumetanide, torsemide) if furosemide is ineffective, as suggested by Kidney International 4
For resistant edema, add thiazide diuretics, amiloride, or spironolactone (with careful monitoring of potassium), as recommended by Kidney International 4

Avoid nephrotoxic medications, including NSAIDs, as advised by the European Heart Journal and other sources 7
Adjust dosages for medications cleared by the kidneys, such as Atenolol, which requires a half dose (50 mg/day) for CrCl between 15-35 mL/min, according to the European Heart Journal 5
Specific anticoagulant considerations, such as Fondaparinux being contraindicated in severe renal failure (CrCl <30 mL/min), are recommended by the European Heart Journal 5
Bivalirudin requires a reduced infusion rate to 1.0 mg/kg/h if CrCl <30 mL/min, as advised by the European Heart Journal 5
Specific antiplatelet considerations, such as Tirofiban, which requires a reduced dose to 50% if CrCl <30 mL/min, are recommended by the European Heart Journal 5
Eptifibatide requires a reduced infusion to 1 mg/kg/min if CrCl <50 mL/min and is contraindicated if CrCl <30 mL/min, as stated by the European Heart Journal 5

Consider referral to a nephrologist given the GFR <60 mL/min for specialized management, as recommended by the American Journal of Kidney Diseases 1

If kidney function continues to decline (GFR <15 mL/min), begin discussions about renal replacement therapy options, including hemodialysis, peritoneal dialysis, transplantation, or conservative management, as advised by the American Journal of Kidney Diseases 8
Preparation for kidney failure should begin when patients reach CKD stage 4 (GFR <30 mL/min), according to the American Journal of Kidney Diseases 8

For patients with GFR <30 mL/min, thiazide diuretics become ineffective and loop diuretics are preferred, as suggested by the European Society of Cardiology 9